Vanguard Group
PBLA

Vanguard Group’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Vanguard Group’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$1.51K – 4662
2022
Q4 		$1.51K Sell
1
-8
-89% -$27.3K ﹤0.01% 4526
2022
Q3 		$60K Buy
+9
New +$189K ﹤0.01% 4534
2022
Q2 		– Sell
-10
Closed -$482K – 4659
2022
Q1 		$482K Hold
10
– – ﹤0.01% 4407
2021
Q4 		$396K Hold
10
– – ﹤0.01% 4468
2021
Q3 		$495K Buy
10
+1
+11% +$58.5K ﹤0.01% 4378
2021
Q2 		$615K Buy
9
+8
+800% +$780K ﹤0.01% 4235
2021
Q1 		$82K Buy
+1
New +$113K ﹤0.01% 4323

Other funds holding PBLA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Vanguard Group's PBLA Position: Q1 2023 in Review

Vanguard Group sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2023, closing a stake of 1 share — an estimated $1.51K sold.

Vanguard Group first reported a position in PBLA in Q1 2021 and held it in 7 quarters. The position peaked at $615K in Q2 2021. 15 funds tracked by Wall St. Rank hold PBLA as of Q1 2023.

  • Vanguard Group reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 1 Panbela Therapeutics, Inc. Common Stock share in Q1 2023, an estimated $1.51K.
  • Vanguard Group first reported a position in Panbela Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Vanguard Group's Panbela Therapeutics, Inc. Common Stock position peaked at $615K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.